Found: 7
Select item for more details and to access through your institution.
Recurrent genital herpes suppressed by oral acyclovir: a multicentre double blind trial.
- Published in:
- 1985
- By:
- Publication type:
- journal article
Oral acyclovir in the suppression of recurrent non-genital herpes simplex virus infection.
- Published in:
- British Journal of Dermatology, 1985, v. 113, n. 6, p. 731, doi. 10.1111/j.1365-2133.1985.tb02409.x
- By:
- Publication type:
- Article
Controlled clinical trial of acyclovir in chronic hepatitis B virus infection.
- Published in:
- Journal of Medical Virology, 1987, v. 21, n. 1, p. 81, doi. 10.1002/jmv.1890210111
- By:
- Publication type:
- Article
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2009, v. 64, n. 2, p. 398
- By:
- Publication type:
- Article
A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients.
- Published in:
- Clinical Infectious Diseases, 2004, v. 39, n. 4, p. 591, doi. 10.1086/422452
- By:
- Publication type:
- Article
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 3, p. 354, doi. 10.1093/infdis/jiu051
- By:
- Publication type:
- Article
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study.
- Published in:
- Journal of Infectious Diseases, 2013, v. 207, n. 5, p. 740
- By:
- Publication type:
- Article